This is a working overview of AOD-9604, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-08-12. Anything still debated is marked as such rather than presented as settled.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
== Prevention == To prevent eclabium, testing for the mutation for ABCA12 gene can be done on the mother to see if the unborn child has the gene. This allows the parents to make a decision accordingly because most children with ABCA12 gene mutation will have eclabium. Healing of wounds near lips or gums should be carefully monitored to prevent severe eclabium. If the improper healing is caught at the right time it can become imperative to prevent the eclabium as soon as possible. Basic dental hygiene can help prevent periodontitis. Basic dental hygiene includes brushing and flossing as well as regular dentist visits. If periodontitis is prevented, it reduces the chances of eclabium caused by poor dental hygiene.
==== France ==== Rungis International Market in the Île-de-France region, created in 1969, is the largest market for fresh food in the whole of Europe, selling food from both within and without Île-de-France. The largest wholesale food market in the world, and perhaps even the largest fresh food market, various foods are offered, including sheep and eel. By 1972, 6000 tonnes of fruits and vegetables were shipped to the market daily.
=== Genes addition, deletion and modification === Recombinant SeV variants has been constructed by introducing new genes and/or by deleting some viral genes such as F, M, and HN from the SeV genome. Reporter genes, such as those that are coding luciferase, green or red fluorescent proteins can be inserted in different locations in the viral genome. These locations include positions upstream of the N gene, between the N and P genes, between P and M, M and F, F and HN, HN and L, and after the L gene. SeV constructs have also been created with a modified protease cleavage site in fusion protein (F). The SeV F protein is a type I membrane glycoprotein that is synthesized as an inactive precursor (F0) that must be activated by proteolytic cleavage at residue arginine-116. After the cleavage F0 precursor yields two disulfide-linked subunits F1 and F2. The proteolytic cleavage site can be changed, so other host proteases would be capable to process F0. Sendai virus based vector system that can deliver CRISPR/Cas9 for efficient gene editing was created.
=== Spectrum of collective cell migration === In the diagram immediately below, different morphologies of collective cell migration are characterized by their cohesiveness during migration (inversely related to density), as well as the number of nearest neighbours with which a cell interacts while moving (i.e. the topological arrangement of individual cells in the population). Cells (ellipses) can migrate in linear chains (top left), with persistent contact to cells either side of them, or along trails formed by preceding cells (bottom left). In migrating sheets, cells may maintain most of their nearest neighbours over time (top right), whereas in streaming migration cell–cell contacts occur at longer range and with potentially frequent neighbour rearrangement (bottom right). These concepts easily extend to three-dimensional migration, in which case the place of migrating sheets can be taken by moving clusters or spheroids.
Sources: en.wikipedia.org
Hofmeister discovered a series of salts that have consistent effects on the solubility of proteins and (it was discovered later) on the stability of their secondary and tertiary structure. Anions appear to have a larger effect than cations, and are usually ordered
=== Regulation of algicidal activity === To perform algicidal processes, bacteria require mechanisms to detect and regulate their responses. Some common bacterial mechanisms associated with algicidal activities include chemotaxis, attachment and biofilm formation, and quorum sensing.
== Personal life == Crampton was born and grew up in the desert areas on the periphery of Barstow, California. They were nomadic, moving between the United States, Mexico and Bolivia for most of their life, occasionally taking residence in community centers. They took piano and keyboard lessons as a child, and began writing and recording music in 2007, forming the band E&E with Erik Ansaya and Ashland Mines. After finishing up their studio album American Drift (2015) in 2014, they went to Bolivia to care for their grandmother Flora. Chuquimamani-Condori and their brother Joshua identify with the Pakajaqi nation of Aymara people, which descends from the pre-Hispanic Pacajes lordship, located in the modern-day Pacajes Province of Bolivia. They are the great-great-grandchildren of Francisco Tancara and Rosa Quiñones, spiritual leaders from the town of Rosario, Pacajes, who were leaders in indigenous resistance to state authorities in the early 20th century.
Sources: en.wikipedia.org
The simplest PK compartmental model is the one-compartmental PK model. This models an organism as one homogenous compartment. This monocompartmental model presupposes that blood plasma concentrations of the drug are the only information needed to determine the drug's concentration in other fluids and tissues. For example, the concentration in other areas may be approximately related by known, constant factors to the blood plasma concentration. In this one-compartment model, the most common model of elimination is first order kinetics, where the elimination of the drug is directly proportional to the drug's concentration in the organism. This is often called linear pharmacokinetics, as the change in concentration over time can be expressed as a linear differential equation
=== Films and television === Chains (film), a 1949 Italian melodrama film Chains (Blackadder), a 1986 episode of the British sitcom Blackadder II Chain (advertisement), a 1994 television advertisement for Guinness Chains of Love (TV series), a 2001 American dating game show adapted from a Dutch television series Chain (film), a 2004 film written and directed by Jem Cohen Chains, a 2009 short film starring TNA wrestler Kurt Angle
This phase was initially supported by worker remittances from abroad and a sharp rise in exports of labour-intensive goods like textiles. Subsequently service and software exports accelerated as global communication costs fell. Overall, private business investment rose significantly as the Indian government shifted its economic priorities. By the mid-2010s, India's economy was rapidly growing. It led to gains in poverty reduction, increased national tax collection, and a surge in private investment. As the Indian government methodically withdrew from direct investment in industry, it simultaneously increased public spending on vital infrastructure projects to keep pace with accelerating urbanisation. This economic opening also diversified the domestic economy. New industries emerged, most notably in information technology services; the national judicial infrastructure slowly adapted. However, growth was accompanied by widening income gaps, with some data showing only limited gains in overall welfare and everyday quality of life. Moreover, rapid development has exerted accelerated pressure on the environment. In response, activist political movements emerged to resist environmental degradation.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.